Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENVB NASDAQ:JSPR NASDAQ:LPCN NASDAQ:NEUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENVBEnveric Biosciences$1.32+3.9%$1.69$1.26▼$17.64$4.68M1.15112,473 shs83,987 shsJSPRJasper Therapeutics$0.77-5.4%$0.62$0.32▼$3.31$22.79M3.073.11 million shs1.71 million shsLPCNLipocine$2.19+1.9%$2.30$1.81▼$12.37$17.73M0.4445,675 shs16,594 shsNEUPNeuphoria Therapeutics$3.34+1.2%$4.37$3.19▼$21.40$17.83M0.7488,784 shs47,251 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENVBEnveric Biosciences+3.94%0.00%+3.13%-63.33%-91.97%JSPRJasper Therapeutics-5.42%+6.53%+69.98%-21.36%-76.01%LPCNLipocine+1.86%-5.19%-6.01%-9.50%-30.91%NEUPNeuphoria Therapeutics+1.21%-6.44%-22.51%-32.25%-56.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENVBEnveric Biosciences$1.32+3.9%$1.69$1.26▼$17.64$4.68M1.15112,473 shs83,987 shsJSPRJasper Therapeutics$0.77-5.4%$0.62$0.32▼$3.31$22.79M3.073.11 million shs1.71 million shsLPCNLipocine$2.19+1.9%$2.30$1.81▼$12.37$17.73M0.4445,675 shs16,594 shsNEUPNeuphoria Therapeutics$3.34+1.2%$4.37$3.19▼$21.40$17.83M0.7488,784 shs47,251 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENVBEnveric Biosciences+3.94%0.00%+3.13%-63.33%-91.97%JSPRJasper Therapeutics-5.42%+6.53%+69.98%-21.36%-76.01%LPCNLipocine+1.86%-5.19%-6.01%-9.50%-30.91%NEUPNeuphoria Therapeutics+1.21%-6.44%-22.51%-32.25%-56.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENVBEnveric Biosciences 1.00SellN/AN/AJSPRJasper Therapeutics 2.38Hold$12.001,458.44% UpsideLPCNLipocine 2.33Hold$15.00584.93% UpsideNEUPNeuphoria Therapeutics 2.00Hold$21.00528.74% UpsideCurrent Analyst Ratings BreakdownLatest ENVB, LPCN, NEUP, and JSPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026ENVBEnveric Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026JSPRJasper Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/18/2026LPCNLipocine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026NEUPNeuphoria Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/15/2026JSPRJasper Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetSector Perform$4.00 ➝ $3.005/15/2026JSPRJasper Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/15/2026NEUPNeuphoria Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENVBEnveric BiosciencesN/AN/AN/AN/A$7.00 per shareN/AJSPRJasper TherapeuticsN/AN/AN/AN/A$0.15 per shareN/ALPCNLipocine$1.98M9.11N/AN/A$2.61 per share0.84NEUPNeuphoria Therapeutics$15.65M1.15$0.16 per share21.17$10.11 per share0.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENVBEnveric Biosciences-$8.77M-$23.54N/AN/AN/AN/A-220.97%-177.47%8/17/2026 (Estimated)JSPRJasper Therapeutics-$75.80M-$3.23N/AN/AN/AN/A-613.51%-162.52%8/12/2026 (Estimated)LPCNLipocine-$9.63M-$1.88N/AN/AN/A-571.18%-66.70%-59.39%8/4/2026 (Estimated)NEUPNeuphoria Therapeutics-$370K-$11.06N/AN/AN/AN/A-76.93%-54.76%9/2/2026 (Estimated)Latest ENVB, LPCN, NEUP, and JSPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026JSPRJasper Therapeutics-$0.38N/AN/AN/AN/AN/A8/4/2026Q2 2026LPCNLipocine-$0.40N/AN/AN/A$0.21 millionN/A5/15/2026Q1 2026ENVBEnveric BiosciencesN/A-$1.08N/A-$1.08N/AN/A5/15/2026Q3 2026NEUPNeuphoria Therapeutics-$0.56-$0.09+$0.47-$0.09N/AN/A5/14/2026Q1 2026JSPRJasper Therapeutics-$0.46-$0.38+$0.08-$0.04N/AN/A5/7/2026Q1 2026LPCNLipocine-$0.51-$0.54-$0.03-$0.54$0.16 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENVBEnveric BiosciencesN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENVBEnveric BiosciencesN/A11.6611.66JSPRJasper TherapeuticsN/A2.262.26LPCNLipocineN/A9.999.99NEUPNeuphoria TherapeuticsN/A14.3114.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENVBEnveric Biosciences13.82%JSPRJasper Therapeutics79.85%LPCNLipocine9.11%NEUPNeuphoria Therapeutics15.90%Insider OwnershipCompanyInsider OwnershipENVBEnveric Biosciences2.41%JSPRJasper Therapeutics2.30%LPCNLipocine4.69%NEUPNeuphoria Therapeutics1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENVBEnveric Biosciences203.68 million3.59 millionNot OptionableJSPRJasper Therapeutics2028.00 million27.35 millionOptionableLPCNLipocine108.24 million7.86 millionNo DataNEUPNeuphoria TherapeuticsN/A5.40 million5.32 millionN/AENVB, LPCN, NEUP, and JSPR HeadlinesRecent News About These CompaniesNeuphoria Therapeutics Stock Dividends | NASDAQ:NEUP | BenzingaJuly 11, 2026 | benzinga.comMerck axes Alzheimer’s study, adding to partner Neuphoria’s mounting woesJuly 3, 2026 | biospace.comBMerck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelmsJuly 1, 2026 | fiercebiotech.comFMRK, NEUP stocks drop as Merck scraps another Alzheimer’s drug trial under Neuphoria partnershipJuly 1, 2026 | msn.comNeuphoria Therapeutics Inc. Common StockJune 27, 2026 | fxempire.comFNeuphoria Therapeutics in Talks to Be Acquired by Scancell HoldingsJune 27, 2026 | marketwatch.comNeuphoria Responds to the announcement made by London-listed Scancell Holdings plcJune 26, 2026 | globenewswire.comHC Wainwright & Co. downgrades Neuphoria Therapeutics (NEUP)May 17, 2026 | msn.comNeuphoria Therapeutics (NEUP) price target increased by 38.22% to 13.77May 14, 2026 | msn.comHere's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn SituationFebruary 19, 2026 | uk.finance.yahoo.comNeuphoria Therapeutics (NEUP) price target decreased by 32.33% to 9.96December 22, 2025 | msn.comLeading Advisory Firms Recommend Voting FOR Lynx1's Independent NomineesDecember 8, 2025 | marketwatch.comLeading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director NomineesDecember 8, 2025 | markets.businessinsider.comLeading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director NomineesDecember 8, 2025 | globenewswire.comHC Wainwright & Co. maintains Neuphoria Therapeutics (NEUP) buy recommendationDecember 5, 2025 | msn.comNeuphoria Therapeutics price target lowered to $7 from $21 at HC WainwrightDecember 5, 2025 | msn.comNeuphoria Therapeutics responds to Lynx1’s revised indication of interestDecember 4, 2025 | msn.comNeuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and PremiumDecember 4, 2025 | finance.yahoo.comNeuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and PremiumDecember 4, 2025 | globenewswire.comLynx1 Sends Open Letter to Fellow Neuphoria ShareholdersDecember 3, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENVB, LPCN, NEUP, and JSPR Company DescriptionsEnveric Biosciences NASDAQ:ENVB$1.32 +0.05 (+3.94%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$1.33 +0.01 (+1.06%) As of 07/21/2026 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Jasper Therapeutics NASDAQ:JSPR$0.77 -0.04 (-5.42%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$0.81 +0.04 (+4.81%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.Lipocine NASDAQ:LPCN$2.19 +0.04 (+1.86%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$2.23 +0.04 (+1.78%) As of 07/21/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Neuphoria Therapeutics NASDAQ:NEUP$3.34 +0.04 (+1.21%) Closing price 07/21/2026 03:59 PM EasternExtended Trading$3.38 +0.04 (+1.35%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings 3 Photonics Companies Making Quantum Tech Possible Confidence Is Back, But Earnings Show the Consumer Is Being Picky Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
